Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Change in Acquisitions & Divestments came in at $209.0 million in Q1 2026, down 4.13% year-on-year from $218.0 million in Q1 2025, and down 4.57% quarter-over-quarter from $219.0 million in Q4 2025.
Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Change in Acquisitions & Divestments across 18 years of filings, most recently posting $209.0 million for Q1 2026.
- Change in Acquisitions & Divestments for Q1 2026 came in at $209.0 million, down 4.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 2.88% YoY), and the FY2025 annual result was $1.7 billion, down 32.53% from the prior year.
- Change in Acquisitions & Divestments came in at $209.0 million for Q1 2026 at Johnson & Johnson, down from $219.0 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $24.8 billion in Q1 2023 to a low of $209.0 million in Q1 2026.
- The 5-year median for Change in Acquisitions & Divestments is $735.0 million (2025), against an average of $3.7 billion.
- Across the five-year window, Change in Acquisitions & Divestments climbed 23.21% in 2023 and tumbled 91.95% in 2024, its largest moves.
- Johnson & Johnson's Change in Acquisitions & Divestments stood at $6.3 billion in 2022, then sank by 42.84% to $3.6 billion in 2023, then sank by 91.95% to $290.0 million in 2024, then dropped by 24.48% to $219.0 million in 2025, then declined by 4.57% to $209.0 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $209.0 million (Q1 2026), $219.0 million (Q4 2025), and $489.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 209.00 Mn |
| Mar 29, 2026 | 209.00 Mn |
| Dec 28, 2025 | 219.00 Mn |
| Dec 28, 2025 | 219.00 Mn |
| Sep 28, 2025 | 489.00 Mn |
| Sep 28, 2025 | 489.00 Mn |
| Jun 29, 2025 | 735.00 Mn |
| Jun 29, 2025 | 735.00 Mn |
| Mar 30, 2025 | 218.00 Mn |
| Mar 30, 2025 | 218.00 Mn |
| Dec 29, 2024 | 290.00 Mn |
| Dec 29, 2024 | 290.00 Mn |
| Sep 29, 2024 | 466.00 Mn |
| Sep 29, 2024 | 466.00 Mn |
| Jun 30, 2024 | 727.00 Mn |
| Jun 30, 2024 | 727.00 Mn |
| Mar 31, 2024 | 979.00 Mn |
| Mar 31, 2024 | 979.00 Mn |
| Dec 31, 2023 | 3.60 Bn |
| Dec 31, 2023 | 3.60 Bn |